Recomendaciones de buena práctica en el tratamiento de la dislipemia en la diabetes

  1. Hormigo Pozo, Antonio
  2. Mancera Romero, José
  3. Pérez Unanua, María Paz
  4. Alonso Fernández, M.
  5. López Simarro, F.
Journal:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Year of publication: 2015

Issue: 2

Pages: 89-98

Type: Article

DOI: 10.1016/J.SEMERG.2014.11.007 DIALNET GOOGLE SCHOLAR

More publications in: Semergen: revista española de medicina de familia

Abstract

People with type 2 diabetes mellitus have a 2 to 4 times higher risk of developing cardiovascular diseases when compared to general population of similar age and sex. This risk remains after adjustment of other traditional cardiovascular risk factors. The dyslipidemia associated with type 2 diabetes mellitus is present in up to 60% of people with diabetes and contributes greatly to increased cardiovascular, morbidity and mortality risk in these patients. Diabetic dyslipidemia is a disorder of lipid metabolism characterized by an excess of triglycerides, a decrease in HDL-cholesterol and altered lipoprotein composition, consisting mainly in an excess of small, dense LDL particles. Multiple clinical trials have demonstrated the benefits of drug treatment of dyslipidemia (mainly statins) to prevent cardiovascular events and mortality in people with diabetes, both in primary and secondary prevention. This consensus document, developed by general practitioners, members of the Diabetes Group of the Spanish Society of Primary Care Physicians (SEMERGEN), aims to assist in the management of patients with diabetes and dyslipidemia in accordance with the most recent recommendations.